CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Spectral Medical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Spectral Medical Inc
135 The West Mall, Unit 2
Phone: (416) 626-3233p:416 626-3233 TORONTO, ON  M9C 1C2  Canada Ticker: EDTXFEDTXF

Business Summary
Spectral Medical Inc. is a Canada-based company that develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's EAA. It is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development as well as in products manufactured by other diagnostic companies. The Company through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. Its dialysis machine, SAMI is targeting the acute RRT market, while its home hemodialysis machine, DIMI is targeting the chronic RRT market.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Anthony P.Bihl 66 5/23/2013 3/7/2008
President, Director Paul M.Walker 4/1/2021 4/1/2001
Chief Executive Officer, Director ChrisSeto 6/7/2023 8/2/2019
6 additional Officers and Directors records available in full report.

Business Names
Business Name
EDTXF
Spectral Diagnostics (US) Inc.
Spectral Diagnostics, Inc
Spectral Diagnostics, Inc (USA)

General Information
Number of Employees: 32 (As of 12/31/2022)
Outstanding Shares: 278,576,261 (As of 7/28/2023)
Shareholders: 190
Stock Exchange: OTC
Fax Number: (416) 626-3233
Email Address: lpipe@spectraldiagnostics.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023